SCHEMBL12233411

SCHEMBL12233411

COc1ccc(C#Cc2nc3c([nH]2)c(=O)[nH]c(=O)n3N(C)C)cc1OC

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.35
▸ KDM4C Q9H3R0 1/20 0.35
▸ CYP2C9 P11712 1/20 0.34
▸ ENPP1 P22413 1/20 0.34
▸ MPO P05164 1/20 0.33
▸ XDH P47989 1/20 0.33
▸ ADORA2A P29274 2/20 0.33
▸ ADORA1 P30542 1/20 0.33
▸ ACACB O00763 2/20 0.33
▸ GAA P10253 2/20 0.33
▸ MAPT P10636 2/20 0.33
▸ MAPK1 P28482 2/20 0.33
▸ TP53 P04637 1/20 0.33
▸ TSHR P16473 1/20 0.33
▸ XBP1 P17861 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ ATM Q13315 1/20 0.33
▸ SMN1; SMN2 Q16637 1/20 0.33
▸ NPSR1 Q6W5P4 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2536378 0.85 ADORA2A (0.41) KDM4ECYP2C9ADORA2AADORA1GAA
SCHEMBL12233446 0.79 ADORA3 (0.35) ADORA2AADORA1
SCHEMBL12233436 0.79 MEN1 (0.38) KDM4EKDM4CCYP2C9MAPTMAPK1
SCHEMBL8174005 0.79 ADORA2A (0.52) KDM4EADORA2AADORA1MAPTKMT2A
SCHEMBL2536377 0.69 ADORA2B (0.40) KDM4ECYP2C9ADORA2AADORA1MAPK1
SCHEMBL2541211 0.69 ADORA2B (0.47) ADORA2A
SCHEMBL8182463 0.69 KDM4E (0.54) KDM4EMAPTXBP1KMT2ASMN1; SMN2
SCHEMBL12233427 0.67 KDM4E (0.38) KDM4EACACBMAPTMAPK1TSHR
SCHEMBL2537017 0.66 KDM4E (0.47) KDM4ECYP2C9ADORA2AADORA1GAA
SCHEMBL16641175 0.64 CA2 (0.54) KDM4ECYP2C9ACACBMAPK1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097415-B1 8-ETHINYLXANTHINE DERIVATIVES AS SELECTIVE A2A RECEPTOR ANTAGONISTS UNIV BONN (DE) 2014-10-29 — — EP disclosed
US-8044061-B2 Parkinson's disease, catalepsy, dystonia, dyskinetic syndrome, restless legs syndrome, migraine, pain, dementia, neurodegenerative disorders, alcohol withdrawal and/or ischemic conditions such as e.g. stroke or cardiac ischemia. UCB PHARMA GMBH (DE) 2011-10-25 — — US disclosed
US-20080221134-A1 8-ALKYNYLXANTHINES AND DERIVATIVES RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAET BONN (DE) 2008-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080221134-A1 8-ALKYNYLXANTHINES AND DERIVATIVES SLC6A3, PARK7, SLC18A2 KDM4E 3538/4885KDM4C 3985/4885CYP2C9 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback